FDA CANCELS MEETING ON POSSIBLE PART 11 REVISIONS

Washington Drug Letter
KEYWORDS FDA / Part 11
A A

The FDA’s decision last week to cancel its June 11 public meeting to address possible Part 11 rule revisions created even more confusion in the industry, which has been struggling to get a clear fix on the agency’s direction regarding electronic signatures and electronic recordkeeping.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00